Clinical Trials Logo

Clinical Trial Summary

- To find out the gap between real-world clinical practice and guideline recommendations in initial management of DTC patients

- To observe the characteristics of patients who achieved and did not achieve TSH target value after one year follow-up

- To assess response to initial therapy in patients who undergo total or near-total thyroidectomy and RAI remnant ablation after one year follow-up (according to an modified dynamic risk stratification system)

- To observe the recurrence status after one year follow-up


Clinical Trial Description

Multi-center, prospective, registry study

2000 DTC patients undergo the first-time thyroidectomy and identified as intermediate or high risk of recurrence will be recruited. Doctors can treat the patients based on disease conditions. Investigators will record data which are related to study endpoints.

Primary endpoint(s):

1. Proportion of patients who underwent total/near-total thyroidectomy

2. Proportion of patients who were treated by 131I after undergoing total/near-total thyroidectomy

3. Proportion of patients who achieved serum TSH target value

4. Proportion of patients who did not achieve serum TSH target value although they were treated by TSH suppression therapy

Secondary endpoint(s):

1. Time to achieve serum TSH target value

2. Dosage of L-T4 for patients who achieved and did not achieve serum TSH target value

3. Dosage of L-T4 per kilogram of body weight for patients who achieved and did not achieve serum TSH target value

4. Proportion of excellent response/Acceptable response/Biochemical incomplete response/Structural incomplete response to initial management in patients who undergo total or near-total thyroidectomy and RAI remnant ablation after one year follow-up

5. Recurrence rate after one year follow-up

6. AEs related to L-T4 (or thyroid tablet)treatment ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02638077
Study type Observational
Source Huazhong University of Science and Technology
Contact Jie Ming, Doctor of Medicine
Phone 8610 02785351622
Email mingjiewh@126.com
Status Recruiting
Phase N/A
Start date October 2015
Completion date April 2017

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02870569 - Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer Phase 2
Completed NCT01876784 - Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Phase 3
Completed NCT04971473 - Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal Phase 3
Recruiting NCT04964284 - Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer Phase 3
Recruiting NCT05078853 - Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
Active, not recruiting NCT03690388 - A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy Phase 3
Recruiting NCT01700699 - Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors N/A
Completed NCT03176485 - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors N/A
Recruiting NCT04563780 - The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer
Completed NCT03191643 - PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer N/A
Completed NCT02278198 - Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123 Phase 1
Active, not recruiting NCT04447183 - The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. Phase 2
Active, not recruiting NCT01263951 - Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone Phase 2
Recruiting NCT04940052 - Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer Phase 3
Recruiting NCT04880798 - Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer N/A
Recruiting NCT05789667 - Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
Recruiting NCT05660954 - Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. Phase 2
Completed NCT00295763 - A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Phase 3
Recruiting NCT04321954 - Lenvatinib in Locally Advanced Invasive Thyroid Cancer Phase 2